Trials / Recruiting
RecruitingNCT06030843
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 10 MG | Empagliflozin 10 MG |
| DRUG | Placebo | Matching placebo containing Lactose content (0.26 gram) |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2025-11-30
- Completion
- 2026-12-31
- First posted
- 2023-09-11
- Last updated
- 2025-08-07
Locations
1 site across 1 country: Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06030843. Inclusion in this directory is not an endorsement.